vs Latanoprost

Achieve the IOP response you expect from a lipid in more patients
LUMIGAN offers better mean IOP reduction than latanoprost
LUMIGAN offers greater mean IOP reduction than latanoprost
Over 24 hours, LUMIGAN offers greater mean IOP reduction than latanoprost
Real-life evaluation demonstrates LUMIGAN achieves superior mean IOP-lowering efficacy to latanoprost

Nonresponders

LUMIGAN succeeds in vast majority of latanoprost nonresponders
Latanoprost nonresponders likely to achieve success with LUMIGAN

Achieve the IOP response you expect from a lipid in more patients

Patients achieving specific IOP reduction at 6 months, noon time point ^10,16

Nearly twice the percentage of LUMIGAN patients achieved ≥ 30% reduction in IOP than latanoprost patients.^10,16

Data were from a 6-month, multicenter, prospective, randomized, investigator-masked, parallel-group comparison with pretrial washout of patients randomized to receive either LUMIGAN QD or latanoprost QD. Measurement visits were at week 1 and months 1, 3, and 6 (N = 269).

Back to top

LUMIGAN offers better mean IOP reduction than latanoprost

Reduction in IOP from baseline ⁵

LUMIGAN achieves greater reduction

Data were from a 30-day, multicenter, double-masked, randomized, clinical trial of 64 patients diagnosed with primary open-angle glaucoma or ocular hypertension. Patients were randomly assigned to receive bimatoprost 0.03% or latanoprost 0.005% or vehicle in both eyes once daily in the evening for 29 days. Measurements were taken at days 14 and 29 at 8 AM. Between-group difference did not reach statistical significance.

Back to top

LUMIGAN offers greater mean IOP reduction than latanoprost

Unadjusted 8 AM mean IOP levels by treatment and visit (intent-to-treat population) ¹¹

LUMIGAN achieves lowest mean IOP

Data were from a 12-week, randomized, parallel-group study conducted at 45 US sites of patients previously treated for open-angle glaucoma or ocular hypertension with an IOP ≥ 23 mm Hg in one or both eyes. After washout of previous medication, patients received either latanoprost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening. Measurements were taken at 8 AM, 12 noon, 4 PM, and 8 PM at baseline and weeks 6 and 12. Differences among groups were not statistically significant.

Back to top

Over 24 hours, LUMIGAN offers greater mean IOP reduction than latanoprost

Mean IOP over 24 hours ²⁴

LUMIGAN achieves lowest 24-hour mean IOP

Study was a 1-month, randomized, multicenter, investigator-masked, parallel-group clinical trial. Patients were randomly assigned to 1 month of treatment with bimatoprost 0.03%, timolol ophthalmic gel-forming solution, or latanoprost 0.005% ophthalmic solution. Visits were at prestudy, baseline (day 0, at least 2 days after prestudy visit), and days 14, 27, and 28 and measured at 8 time points.

Back to top

Real-life evaluation demonstrates LUMIGAN achieves superior mean IOP-lowering efficacy to latanoprost

Effects of LUMIGAN replacement of latanoprost therapy on mean IOP ⁸

3.6 mm Hg additional reduction

Study was an open-label, noncomparative surveillance trial involving 6767 patients from over 1400 clinical sites with over 1400 physicians. Data presented represented a subgroup of 574 patients who were on latanoprost monotherapy prior to the use of LUMIGAN.

Back to top

LUMIGAN succeeds in vast majority of latanoprost nonresponders

Diurnal mean IOP at end of treatment phase ¹⁷

Response with LUMIGAN

Data were from a randomized, prospective, crossover clinical trial of 15 patients with primary open-angle glaucoma or ocular hypertension and documented medical history consistent with < 10% IOP decrease in both eyes upon previous 2-month treatment with latanoprost 0.005% QD. Following a 30-day washout period, patients received either latanoprost or bimatoprost treatment for 30 days. Patients then underwent a second 30-day washout period and were assigned the converse drug for 30 days. Data presented represent pooled information.

Back to top

Latanoprost nonresponders likely to achieve success with LUMIGAN

Mean IOP reduction from baseline in treated eyes during phase 1 (latanoprost treatment) and phase 2 (LUMIGAN treatment) ¹⁸

Nonresponders achieve 3.5 mm Hg greater reduction

Data were from an open-label, monocular, 2-phase trial conducted to determine whether bimatoprost is effective in patients with open-angle glaucoma or ocular hypertension not responsive to latanoprost. After a 4-week washout of any ocular hypertensive agents, patients with IOP between 22 and 34 mm Hg (n = 51) instilled latanoprost in one eye and were evaluated at weeks 4 and 8 (phase 1). Patients with an IOP reduction no more than 3 mm Hg at both visits were considered nonresponders to latanoprost and were switched to bimatoprost for 8 weeks (n = 21) (phase 2).

Back to top